| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ... New England Journal of Medicine 376 (7), 629-640, 2017 | 3661 | 2017 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 981 | 2018 |
| Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study CM Rudin, MM Awad, A Navarro, M Gottfried, S Peters, T Csőszi, ... Journal of Clinical Oncology 38 (21), 2369-2379, 2020 | 617 | 2020 |
| CNS efficacy of osimertinib in patients with T790M-positive advanced non–small-cell lung cancer: data from a randomized phase III trial (AURA3) YL Wu, MJ Ahn, MC Garassino, JY Han, N Katakami, HR Kim, R Hodge, ... Journal of Clinical Oncology 36 (26), 2702-2709, 2018 | 475 | 2018 |
| Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement SM Lim, HR Kim, JS Lee, KH Lee, YG Lee, YJ Min, EK Cho, SS Lee, ... Journal of clinical oncology 35 (23), 2613-2618, 2017 | 369 | 2017 |
| Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Clinical Oncology 38 (31), 3592-3603, 2020 | 332 | 2020 |
| Brigatinib versus crizotinib in ALK inhibitor–naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Thoracic Oncology 16 (12), 2091-2108, 2021 | 305 | 2021 |
| PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients HR Kim, SJ Ha, MH Hong, SJ Heo, YW Koh, EC Choi, EK Kim, KH Pyo, ... Scientific reports 6 (1), 36956, 2016 | 287 | 2016 |
| Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer CG Kim, KH Kim, KH Pyo, CF Xin, MH Hong, BC Ahn, Y Kim, SJ Choi, ... Annals of Oncology 30 (7), 1104-1113, 2019 | 271 | 2019 |
| Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases SH Cheon, SY Rha, HC Jeung, CK Im, SH Kim, HR Kim, JB Ahn, JK Roh, ... Annals of oncology 19 (6), 1146-1153, 2008 | 259 | 2008 |
| Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC J Yun, SH Lee, SY Kim, SY Jeong, JH Kim, KH Pyo, CW Park, SG Heo, ... Cancer Discovery 10 (8), 1194-1209, 2020 | 252 | 2020 |
| Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451 TK Owonikoko, K Park, R Govindan, N Ready, M Reck, S Peters, ... Journal of Clinical Oncology 39 (12), 1349-1359, 2021 | 234 | 2021 |
| Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer HR Kim, DJ Kim, DR Kang, JG Lee, SM Lim, CY Lee, SY Rha, MK Bae, ... Journal of clinical oncology 31 (6), 731-737, 2013 | 208 | 2013 |
| Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement HR Kim, HS Shim, JH Chung, YJ Lee, YK Hong, SY Rha, SH Kim, SJ Ha, ... Cancer 118 (3), 729-739, 2012 | 185 | 2012 |
| Prevalence and prognostic implications of psychological distress in patients with gastric cancer GM Kim, SJ Kim, SK Song, HR Kim, BD Kang, SH Noh, HC Chung, ... BMC cancer 17, 1-8, 2017 | 175 | 2017 |
| Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma CG Kim, C Kim, SE Yoon, KH Kim, SJ Choi, B Kang, HR Kim, SH Park, ... Journal of hepatology 74 (2), 350-359, 2021 | 167 | 2021 |
| Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer JW Cho, MH Hong, SJ Ha, YJ Kim, BC Cho, I Lee, HR Kim Experimental & molecular medicine 52 (9), 1550-1563, 2020 | 162 | 2020 |
| Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak, HY Lee, JM Sun, ... Oncotarget 7 (6), 6984, 2016 | 161 | 2016 |
| The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma HR Kim, SM Lim, HJ Kim, SK Hwang, JK Park, E Shin, MK Bae, SHI Ou, ... Annals of oncology 24 (9), 2364-2370, 2013 | 156 | 2013 |
| Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status YJ Cha, HR Kim, CY Lee, BC Cho, HS Shim Lung cancer 97, 73-80, 2016 | 155 | 2016 |